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Accumulating evidence indicates that therapies designed to trigger apoptosis in tumor cells cause mitochondrial depolarization,
nuclear damage, and the accumulation of misfolded protein aggregates, resulting in the activation of selective forms of autophagy.
These selective forms of autophagy, including mitophagy, nucleophagy, and ubiquitin-mediated autophagy, counteract apoptotic
signalsbyremovingdamagedcellularstructuresandbyreprogrammingcellularenergymetabolismtocopewiththerapeuticstress.
As a result, the eﬃcacies of numerous current cancer therapies may be improved by combining them with adjuvant treatments
that exploit or disrupt key metabolic processes induced by selective forms of autophagy. Targeting these metabolic irregularities
represents a promising approach to improve clinical responsiveness to cancer treatments given the inherently elevated metabolic
demands of many tumor types. To what extent anticancer treatments promote selective forms of autophagy and the degree to
which they inﬂuence metabolism are currently under intense scrutiny. Understanding how the activation of selective forms of
autophagy inﬂuences cellular metabolism and survival provides an opportunity to target metabolic irregularities induced by these
pathways as a means of augmenting current approaches for treating cancer.
1.Introduction
In order to evade barriers against cancer progression and
treatment resistance, tumor cells undergo metabolic adapta-
tions and develop mechanisms to resist apoptosis [1]. Apop-
tosis resistance in tumor cells can occur through multiple
changes, none of which are mutually exclusive. For example,
tumor cells enhance antiapoptotic signaling pathways and
upregulate the removal or repair of damaged DNA as well
as denatured proteins. Overcoming stressors that activate
apoptosis requires higher rates of energy production and
necessitates that tumor cells make metabolic changes to sus-
tain antiapoptotic signaling, DNA repair mechanisms, and
elevated protein turnover. While anticancer therapies that
targettheseessentialprocesseshavebeenproveneﬀective[2–
4], improved outcomes may be achieved by combining them
with metabolic inhibition.
Metabolic inhibitors have been shown to improve the
eﬃcacy of standard therapies in various cancer types [5–8].
Furthermore, the increase in toxicity that is achieved when
metabolic inhibitors are combined with standard therapies
is often well tolerated clinically, supporting the feasibility
of this approach for treating cancer [9, 10]. As a result,
there is a need to increase the development of therapeutic
strategies that exploit key metabolic processes in tumors,
while having minimal impact on normal cells. Anticancer
drugs designed to activate apoptosis by causing mitochon-
drial depolarization, DNA damage, and misfolded protein
aggregatesrestructurecellularmetabolism in waysthatcould
be targeted to enhance the selective killing of tumor cells.
Stress induced by these drugs activates selective forms of
autophagy that could play a central role in reprogramming
cellular metabolism in tumor cells following exposure to
anticancer therapy.
During autophagy, double-membraned vacuoles seques-
ter bulk cytoplasm and whole organelles (so-called macro-
autophagy), or engulf selective cargo for degradation. In
recent years, it has been discovered that autophagy selec-
tively degrades damaged cellular constituents, such as the
mitochondria (mitophagy) and portions of the nucleus2 International Journal of Cell Biology
(nucleophagy), as well as misfolded protein aggregates
(ubiquitin-mediatedautophagy),duringspeciﬁctypesofcel-
lular stress [11–13]. In the following sections, we review gen-
eral features of autophagy as well as unique characteristics of
mitophagy,nucleophagy,andubiquitin-mediatedautophagy
and consider how mitochondrial depolarization, nuclear
damage, and the accumulation of misfolded protein aggre-
gates induced by anticancer agents may impact tumor cell
metabolism and viability.
2. GeneralFeatures of Autophagy
Selective forms of autophagy share many common features
with macroautophagy. It should be noted that the pre-
cise localization signals and protein-protein mediators of
selective autophagy have not been fully deﬁned; however
evidence suggests that structures within the cell are degraded
using components of the general autophagy machinery.
An elongating phagophore encapsulates cellular cargo in a
double-membraned vacuole called an autophagosome and
fuses with lysosomes, resulting in the hydrolytic digestion of
the autophagosome contents. Permeases eﬄux the digested
cargo from the degradative compartment into the cytosol
where molecules serve as either metabolic or biosynthetic
precursors. To date, over 30 autophagy-related proteins have
been reported downstream of the mammalian target of
rapamycin (mTOR), a serine/threonine kinase and master
regulator of autophagy [14]. When mTOR is inhibited, it
ceases to negatively regulate autophagy [15, 16]. Central to
the autophagy pathway is the Beclin1/Vps34 (phosphatidyl-
inositol-3 kinase (PI3K) class III) complex, the ULK com-
plex, and two ubiquitin-like systems: the Atg12-Atg5 conju-
gationsystemandtheAtg8/microtubule-associatedprotein1
light chain 3 (LC3) conjugation system [17–21]. In addition,
other factors, such as Atg9L1, appear to be indispensable for
autophagy to occur [22]. There are likely other converging
pathways required for induction of autophagy and these
may be context dependent. Collectively, these components
appear to play integral roles in mediating autophagosome
formation, elongation, and closure [17–21]. For a detailed
discussion of the autophagy signal transduction cascade, the
reader is directed to several recent reviews [23, 24]. Here,
we focus on key components of the general autophagic
machinery and consider how they interact with unique
factors associated with various forms of selective autophagy.
3. Mitophagy
3.1. The Mitophagy Pathway. While studying the process
of organelle turnover, it was assumed that autophagic
degradation of mitochondria was a random process because
autophagosomes were observed to contain a variety of cyto-
plasmic components including proteins, endoplasmic retic-
ulum, peroxisomes, and mitochondria [25]. However, recent
evidence suggests that autophagic digestion of mitochondria
isaselectiveprocess[26](Figure 1).Onewaythatmitophagy
can be induced is by the opening of mitochondrial mem-
brane permeability transition pores (mPTP) and the depo-
larization of the electrochemical proton gradient across
the inner mitochondrial membrane [11, 27, 28]. Following
mitochondrial membrane potential (ΔΨm) depolarization,
PTEN-induced putative kinase 1 (PINK1) localizes to the
mitochondria and recruits Parkin, an E3 ubiquitin ligase that
forms polyubiquitin chains linked through K27 and K63 on
voltage-dependent anion channel (VDAC) proteins on the
outer membrane of mitochondria [28]. These polyubiquitin
chains appear to serve two purposes: ﬁrst, to tether clusters
ofdysfunctionalmitochondriatogetherandsecond,totarget
these structures for autophagic degradation [28]. Interest-
ingly, both K27 and K63 polyubiquitin linkages have been
correlated with lysosomal localization and/or autophagic
degradation of proteins [28–30]. These linkages diﬀer from
the canonical G76–K48 ubiquitin linkages characteristic of
proteins destined for proteasomal degradation [31, 32],
supporting the hypothesis that site-speciﬁc ubiquitination
targets mitochondria for selective autophagic degradation.
The mechanisms responsible for ushering ubiquitinated
mitochondria to the nascent phagophore for autophagic
degradation are controversial. Initially, Geisler et al. pro-
posed p62 to be the principle mediator of crosstalk between
the selective and degradative machinery of mitophagy, as
silencing of p62 was observed to inhibit the degradation
of mitochondria, polyubiquitin, and Parkin but not the
colocalization of these structures following ΔΨmd e p o -
larization [28]. This hypothesis is supported by evidence
demonstrating that p62 binds K63-linked polyubiquitin
[33] as well as the lipidated form of the autophagosome
bound protein, LC3 [34], which plays an important role
in autophagosome formation and closure [35]. However,
contrary to the results of Geisler et al., two recent studies
have independently demonstrated that p62 is essential for
clustering but not degradation of depolarized mitochondria
[36, 37]. These disparate results are diﬃcult to reconcile
given that the investigators used the same cell types and
siRNAs in their respective studies [28, 36]. However, the
existence of p62-independent mitophagy does not exclude
the possibility that multiple adapter molecules capable of
binding polyubiquitin and LC3 such as p62, Nrb1, and Nix
function redundantly to bridge the selective and degradative
machinery of mitophagy [36, 37].
In addition to the selective machinery described above,
the process of mitophagy also employs conventional proteins
associated with macroautophagy and thus can be blocked
pharmacologically with general autophagy inhibiting drugs
such as chloroquine, 3-methyladenine, and wortmannin
[38, 39]. These drugs are commonly used inhibitors of
lysosomal acidiﬁcation and autophagy inducing signals
generated by class III PI3Ks. To date, it remains unclear
how the autophagic machinery is activated in concert
with PINK1, Parkin, and p62 during ΔΨm depolarization.
One possibility is that Parkin stimulates the generation of
autophagy inducing signals from the Beclin1/Vps34 class III
PI3K complex by interacting with the autophagy promoting
protein, Ambra1 [40]. In addition, given that mitochondria
are responsible for maintaining the majority of cellularInternational Journal of Cell Biology 3
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Figure 1: Anticancer agents may activate selective forms of autophagy by causing ΔΨm depolarization, nuclear damage, and misfolded
protein aggregates. (1) Drugs that open mPTPs are known to cause ΔΨm depolarization, which may result in the recruitment of PINK1
and Parkin. It is hypothesized that this would promote mitochondrial polyubiquitination and selective targeting to the autophagosome
through the LC3:ubiquitin adapter proteins, such as p62. (2) DNA damaging agents may promote the selective autophagy of structurally
damaged portions of nuclei in mammals in a process dependent on the cleavage of lamin and emerin intermediate ﬁlaments in the nuclear
periplasm. To date, the mammalian adapter proteins that target the autophagosome to the nucleus have not been identiﬁed. (3) Drugs that
inhibit the proteosome are known to cause an accumulation of misfolded protein aggregates in tumor cells, which results in Parkin mediated
polyubiquitination and targeting to the autophagosome through p62.
adenosine triphosphate (ATP) pools, it is likely that energy
sensors detecting increases in the intracellular ratio of
adenosine monophosphate (AMP): ATP, such as 5  AMP-
activated protein kinase (AMPK), activate autophagy during
ΔΨm depolarization.
3.2. Mitophagy Inducing Signals Are Generated by Anticancer
Agents. Many ionophores including carbonyl cyanide m-
chlorophenylhydrazone (CCCP), p-triﬂuoromethoxy car-
bonyl cyanide phenylhydrazone (FCCP), 2,4-dinitrophenol,
and ﬂuoride curcumin derivatives have been demonstrated
to induce mitophagy by causing ΔΨm depolarization [28,
41, 42]. In addition to activating mitophagy, these uncou-
pling agents and numerous other drugs that open mPTPs
cause mitochondrial swelling and depolarization, signaling
for the induction of apoptosis [43]. Among these mPTP
targeting drugs are several clinically used anticancer agents,
including 1-β-D-arabinofuranosylcytosine, butyrate, dox-
orubicin, etoposide, lonidamine, paclitaxel, and vinorelbine
(Table 1). Drugs targeting mPTPs are attractive for cancer
therapy because they mediate cytochrome c release, a potent
apoptotic trigger [43]. While some of these drugs have
been reported to activate autophagy, their ability to induce
mitophagy speciﬁcally has not been investigated. Given
that mitochondrial depolarization is a powerful inducer of
mit ophagyaswellasapopt osis,furtherw orkmustbedonet o
determine whether mPTP targeting drugs do in fact activate
mitophagy and how this impacts cellular viability.
3.3. Implications of Mitophagy on Tumor Cell Metabolism
and Survival during Therapeutic Assault. The fate of cells
that undergo ΔΨm depolarization is dependent on a variety
of factors including the level of apoptotic signaling from
the mitochondria and cellular metabolism. The degradation
of dysfunctional mitochondria by mitophagy promotes cell
survival by preventing the production and release of toxic
byproducts such as reactive oxygen species and cytochrome c
that signal for apoptosis [43, 89]. However, the bioenergetic
consequences of mitophagy on cellular viability are more
complex.Ononehand,homeostaticlevelsofmitophagymay
promote cell survival by liberating metabolites that can be
oxidized in functional mitochondria for energy. Conversely,
hyperactivation of mitophagy renders cells either incapable
of meeting energetic demands or solely dependent upon
glycolytic substrates for survival [41]. Given that many
tumors are inherently dependent on aerobic glycolysis for
bioenergetics (so-called Warburg eﬀect) [90, 91], hyperacti-
vation of mitophagy would solidify their glycolytic addiction4 International Journal of Cell Biology
Table 1: Clinically used anticancer agents that may induce mitophagy, nucleophagy, and ubiquitin-mediated autophagy in tumor cells.
Drug Mechanism of action Cancer type
Conﬁrmed
autophagy
inducer
Mitophagy
1-β-D-arabinofuranosylcytosine DNA synthesis inhibitor [44, 45],
mPTP opener [46] Leukemia [47], lymphoma [48]n o
Butyrate mPTP opener [49, 50]L e u k e m i a [ 51]y e s [ 50]
Doxorubicin mPTP opener [46] Breast [52], lung, melanoma,
sarcoma [53] yes [54]
Etoposide Topoisomerase inhibitor [55],
mPTP opener [46]
Gastric [56], Kaposi’s sarcoma [57],
lung [58] yes [59]
Lonidamine Hexokinase inhibitor [60], mPTP
opener [61] Brain, lung, ovarian [60]n o
Paclitaxel Microtubule stabilizer [62], mPTP
opener [63]
Breast [64], head and neck [65],
Kaposi’s sarcoma [66], lung [67],
ovarian [68]
yes [69]
Vinorelbine Microtubule formation inhibitor,
mPTP opener [70] Breast [71], lung [72]y e s [ 73]
Nucleophagy
1-β-D-arabinofuranosylcytosine DNA synthesis inhibitor [44, 45],
mPTP opener [46] Leukemia [47], lymphoma [48]n o
Camptothecin Topoisomerase inhibitor [74] Gastric [75], lung [76], pancreatic
[77] yes [78]
Cisplatin DNA intercalating agent [79]O v a r i a n [ 68], lung [68]y e s [ 80]
Etoposide Topoisomerase inhibitor [55],
mPTP opener [46]
Lung [58], gastric [56], Kaposi’s
sarcoma [57] yes [59]
Ubiquitin-mediated autophagy
Bortezomib Proteasome inhibitor [81–83] Mantle cell lymphoma [84], multiple
myeloma [85] yes [81–83]
NPI-0052 Proteasome inhibitor [86] Leukemia [87], multiple myeloma
[88] yes [86]
by diverting the ﬂux of metabolites away from the mitochon-
dria.Evidenceinsupportofthishypothesishasbeendemon-
strated in HeLa cells, a human tumor cell line that does
not endogenously express Parkin, and thus cannot undergo
ΔΨm depolarization-induced mitophagy [41]. When HeLa
cells are pretreated with the ΔΨm depolarizing agent, CCCP,
the cells survive, presumably because they are able to utilize
amino acids and other metabolites in the mitochondria to
generate energy [41]. However, HeLa cells pretreated with
CCCP and transfected with Parkin do not survive glucose
withdrawal because their mitochondria are degraded by
mitophagy, preventing oxidative metabolic pathways from
sustaining energy pools [41]. In this model, it appears
that Parkin-dependent mitophagy may promote survival by
coordinating a metabolic shift from oxidative phosphoryla-
tion to glycolysis when mitochondria become dysfunctional.
However, when cells undergo excessive mitophagy, the
nutrient environment of the cell dictates whether cells will
survive or succumb to energy crisis followed by cell death
(Figure 2).
This ﬁnding may have important implications for
chemotherapeutic strategies for treating some cancers. For
example, administration of glycolytic inhibitors in com-
bination with mitophagy inducing chemotherapies may
potentiate killing of tumor cells as a result of increased
tumor cell dependency on glycolysis following excessive
mitophagy. This may explain why the eﬃcacies of several
chemotherapies that result in mPTP opening, such as
paclitaxel and doxorubicin, are enhanced signiﬁcantly when
administered with lonidamine, a combinatorial hexokinase
inhibitor and mPTP opener [92, 93].
4.Nucleophagy
4.1. Nucleophagy Pathway in Saccharomyces cerevisiae and
Mammals. Maintaining proper structure, organization, and
dynamics of the nucleus is essential for the vitality of
most cell types [94]. Emerging evidence suggests that the
selective digestion of portions of the nucleus by autophagy
plays a central role in upholding nuclear integrity when
structural damage occurs [12]. While nucleophagy in mam-
malian cells has recently been reported [12, 95–97], this
process has primarily been described in yeast [94]. In most
yeast models, nutrient deprivation is the stressor of choice
used to induce nucleophagy [98, 99]. Following nutrient
deprivation, junctions between nuclei and vacuoles (the
yeast lytic compartment) are seen to increase in surfaceInternational Journal of Cell Biology 5
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Figure 2: Mitophagy, nucleophagy, and ubiquitin-mediated autophagy are associated with cell survival or cell death depending on the level
of activation. A homeostatic level of mitophagy promotes cell survival by liberating nutrients and by clearing dysfunctional mitochondria
that signal for apoptosis. Conversely, hyperactivation of mitophagy can lead to a loss in the cell’s ability to generate ATP, resulting in cell
death. Similarly, a homeostatic level of nucleophagy protects cells against the accumulation of structural damage to the nucleus and may
provide energetic and biosynthetic resources that aid in repair. Nucleophagy also appears to be associated with cell death in specialized cell
types facing extreme stress. Ubiquitin-mediated autophagy appears to function solely as a survival pathway that clears misfolded protein
aggregates and liberates metabolites that may be used for energy production.
area as a result of interactions between Nvj1p, an outer
nuclearmembraneprotein,andVac8p,avacuolarmembrane
protein [98]. Within nucleus-vacuole junctions, the nuclear
envelope begins to form bulges and blebs that pinch oﬀ
and are sequestered in the vacuole for degradation [99].
This gradual degradation of nuclear content is referred to
as piecemeal microautophagy of the nucleus (PMN) [99].
In contrast to macroautophagy, PMN does not involve the
formation of autophagosomes to envelop content to be
degraded [99].However,ithasbeenshown thatnucleophagy
in yeast requires macroautophagic machinery, including the
two ubiquitin-like conjugation systems and the PI3K class III
complex, to mediate terminal vacuole enclosure and fusion
stages [100].
In contrast to PMN seen in yeast, mammalian cells un-
dergoing nucleophagy are able to form large autophagos-
omes characteristic of macroautophagy [12, 95–97]. These
large double-membraned macroautophagosomes are ob-
served to colocalize with LC3 and have been seen to envelop
large portions of structurally deformed nuclei as well as
small nuclear blebs [12]. While mammalian orthologs of
n u c l e o p h a g ya d a p t e r ss u c ha sN v j 1 pa n dV a c 8 ph a v en o ty e t
been identiﬁed, it has been shown that mutations in A-type
l a m i n sa n de m e r i ni nL m n a H222P/H222P mouse embryonic
ﬁbroblasts cause structural deformations in the nuclear
envelope resulting in the induction of nucleophagy, possibly
through similar selective adapter proteins to those described
in yeast [12]( Figure 1).
4.2. Nucleophagy Inducing Signals Are Generated by Anti-
cancer Agents. Cancer treatment regimens often include
DNA-damaging agents in an attempt to target the nuclear
content of rapidly dividing cells. One feature of many
DNA-damaging agents is their activation of caspases that
disassemble the nuclear lamina by cleaving lamin inter-
mediate protein ﬁlaments. While lamin cleavage is known
to increase nuclear envelope plasticity and contribute to
nuclear blebbing during apoptosis [101], there is evidence
that it also activates nucleophagy. Park et al. demonstrated6 International Journal of Cell Biology
that mutated lamins lead to deformations in the nuclear
envelope that induced nucleophagy [12]. Therefore, DNA-
damaging agents that disrupt the nuclear envelope may
be predicted to have a similar eﬀect. Some clinically used
anticancer agents that induce DNA damage and lamin
cleavage include etoposide, camptothecin, cisplatin, and 1-
β-d-arabinofuranosylcytosine [102]( Table 1). In addition
to these drugs, the cation vanadyl(IV) has been conﬁrmed
to activate oxidative stress and DNA damage resulting in
nucleophagy of whole chromosomes in mitotic cells [96,
97]. While the exact mechanism of nucleophagy induction
following vanadyl(IV) exposure has not been elucidated, it
is possible that it may involve a similar lamin-dependent
mechanism.
4.3. Implications of Nucleophagy on Tumor Cell Metabolism
andSurvivalduringTherapeuticAssault. Activationofnucle-
ophagyappearstobeadouble-edgedsword.Insomemodels,
activation of nucleophagy in response to DNA damage has
beendemonstratedtopromotecelldeathbydegradingwhole
chromosomes in oxidatively stressed mitotic cells [96, 97].
Similarly, whole autophagic degradation of the nucleus has
been seen in protozoans such as Tetrahymena thermophila,
leading to programmed cell death, albeit through diﬀerent
autophagic machinery than what is observed in yeast or
mammals [103]. In contrast, nucleophagy has also been
demonstrated to promote survival in mammalian cells by
maintaining nuclear structure, and possibly through the
release of nutrients for energy production [12]. To date,
nucleophagy has yet to be deﬁned in tumor cells. However,
several DNA damaging anticancer agents may induce nucle-
ophagy in tumors cells as a result of their ability to cause
cleavage of lamin ﬁlaments [102]( Table 1). Some of these
drugs have also been shown to facilitate a cytoprotective,
autophagy-dependentsurgeofATP[59],raisingthepossibil-
itythatnucleophagycontributesinmediatingthisATPsurge.
It may be that ATP pools are utilized to fuel the energy costly
process of DNA repair, the perpetuation of nucleophagy, or
both. In addition, liberation of nucleic acids through the
nucleophagic degradation of damaged DNA may contribute
to increased rates of DNA repair by providing substrate for
DNA repair enzymes. To counteract the potential protective
role of nucleophagy, anticancer agents that induce this
process could be combined with inhibitors of amino acid
or lipid catabolism (major macromolecules associated with
the nuclear envelope) or inhibitors of nucleophagy itself.
However, given the controversial role of nucleophagy in
promoting cell survival and cell death (Figure 2), further
consideration must be given to systemic inhibition of
nucleophagy for cancer therapy.
Another caveat to the systemic inhibition of nucleophagy
is that this may lead to oﬀ-target toxicity in normal tissue.
By removing the potential survival advantage imparted by
nucleophagy, normal cells with DNA damage caused by
nonspeciﬁc therapeutics may succumb to normal apoptotic
pathways.Inaddition,long-livedcellssuchasneuronaltissue
or immunological memory cells may require nucleophagy
for normal maintenance of nuclear structure. Dysregulation
of this process may lead to unforeseen toxicities in these cell
types.
5.Ubiquitin-MediatedAutophagy
5.1. Ubiquitin-Mediated Autophagy Pathway. Tumor cells
inherently have high levels of misfolded proteins due to
rapid proliferation and increased intracellular acidiﬁcation
caused by lactic acid production during glycolysis [104, 105].
In response to misfolded proteins, cells have been shown
to upregulate molecular chaperones that promote refolding
of denatured proteins, proteasomal degradation of soluble
misfolded proteins, and ubiquitin-mediated autophagy of
proteinaggregates[106–108].Theﬁrstlineofdefenseagainst
an aggregation of misfolded proteins is the activation of
molecular chaperones of the heat shock protein family,
which shield hydrophobic surfaces of denatured proteins
to aid in restoration of proper folding [106]. If denatured
proteins persist, ubiquitin-mediated autophagy is activated
[13]( Figure 1). This process requires an intact micro-
tubule cytoskeleton and the cytoplasmic deacetylase, his-
tone deacetylase 6 (HDAC6), presumably to coordinate the
transport of protein aggregates, autophagic machinery, and
lysosomes [109, 110]. Protein aggregates are subsequently
polyubiquitinated through K63 linkages by E3 ubiquitin
ligases, such as Parkin [111]. This promotes the recruitment
of the autophagosome adapter protein, p62, resulting in
selective autophagic degradation [111, 112]. Similar to
mitophagy, it appears that K63 linked polyubiquitination
selectively targets misfolded proteins to the autophagosome,
while crosstalk with the degradative autophagic machinery is
mediated through adapters such as p62.
The general autophagic machinery appears to be acti-
vated in concert with the selective apparatus of ubiquitin-
mediated autophagy by a variety of mechanisms. Following
an accumulation of unfolded proteins, activating transcrip-
tion factor 4 (ATF4) is stabilized, which promotes the
activation of autophagy by increasing the transcription of
LC3 [81, 113]. In addition, signaling from the IRE1-c-
Jun NH(2)-terminal kinase pathway has been shown to be
necessary for the activation of autophagy in response to
proteasome inhibition [82]. Therefore, it appears that the
general autophagy pathway is activated through convergent
mechanisms in response to unfolded proteins.
5.2. Ubiquitin-Mediated Autophagy Is Induced by Anticancer
Agents. T h eo b s e r v a t i o nt h a tt u m o rc e l l sh a v ee l e v a t e d
levels of misfolded proteins, and thus protein turnover,
has stimulated interest in targeting components of the
proteasome in order to induce proteotoxic stress in tumor
cells [114]. Proteotoxicity refers to molecular damage caused
by misfolded protein aggregates that can lead to organelle
dysfunction and cell death [115]. The most well-known
inhibitor of the proteasome, bortezomib (or Velcade(TM)),
has been tested in numerous recent clinical trials and is now
commonly used for the treatment of multiple myeloma and
mantle cell lymphoma [84, 85]. Bortezomib has also shown
some promise in other cancers, such as prostate cancer andInternational Journal of Cell Biology 7
non-small-cell lung cancer [116, 117]. Since bortezomib and
other proteasome inhibitors, such as NPI-0052, compromise
the cell’s ability to dispose of misfolded proteins, proteasome
inhibition can upregulate ubiquitin-mediated autophagy of
misfolded protein aggregates as a compensatory strategy
[109, 110, 118]( Table 1). Given that autophagy helps cells to
degrade misfolded protein aggregates caused by proteasomal
inhibition [86], it is not surprising that preclinical studies
have reported increased eﬃcacy of proteasomal inhibitors
when coupled with autophagy inhibitors in colon, prostate,
and breast cancer cell types [81–83]. The potential for
increased therapeutic eﬃcacy of proteasomal inhibition
when combined with autophagy inhibition has even led to
the initiation of a clinical trial combining bortezomib with
the autophagy blocking drug, chloroquine, for the treatment
of multiple myeloma (NCT01438177).
5.3.ImplicationsforUbiquitin-MediatedAutophagyonTumor
Cell Metabolism and Survival during Therapeutic Assault.
In contrast to mitophagy and nucleophagy, it is unclear
how the selective autophagy of misfolded proteins may
restructure tumor cell metabolism. Unlike mitophagy, this
process does not appear to skew nutrient utilization toward
any particular pathway. Furthermore, there is no evidence
thattheubiquitin-mediatedautophagyofmisfoldedproteins
promotes bioenergetics in ways similar to nucleophagy.
On the contrary, the fact that tumor cells are capable
of sustaining the energetically costly process of protein
translation to the point where misfolded proteins aggregate
and become toxic indicates that cells undergoing this type
of stress are not lacking intracellular energetic resources.
Collectively, these observations suggest that the ubiquitin-
mediated autophagy of misfolded proteins is activated solely
to remove harmful intracellular structures out of necessity.
However, considering the dynamic metabolic milieu found
in the tumor microenvironment, there may be a yet unde-
ﬁned metabolic advantage to this process over prolonged
periods of time.
As a result of rapid tumor cell proliferation and ﬂuctu-
ations in local vasculature supplying nutrients to the tumor
bed, cancer cells often undergo cycling periods of hypoxia,
and presumably starvation [119]. In order to fuel essential
cellular processes in the absence of exogenous metabolites,
the selective autophagy of misfolded proteins may provide
an internal reserve of nutrients that can be utilized during
cycles of nutrient withdrawal. Therefore, blocking amino
acid catabolism in tumors in vivo may prove to be an
eﬃcacious adjuvant to proteasome inhibition.
6. Conclusion
To date, anticancer agents that nonspeciﬁcally target rapidly
proliferating cells remain the best treatment option for many
forms of cancer. In order to ensure complete killing of
tumor cells, patients are sometimes maintained on these
drugs for years at a time, increasing the probability of
harmful side eﬀects. Consequently, there is a need to develop
strategies to enhance the toxicity of these drugs with greater
speciﬁcity towards tumor cells so that lower doses of cancer
therapeutics can be administered for shorter periods of time
with the same or better antitumor eﬀect.
Irregularmetabolismisafundamentalhallmarkofnearly
all cancerous cells [1]. Therefore, ﬁnding ways to exploit
unique metabolic adaptations and irregularities induced by
anticancer agents in tumors may prove to be an eﬀective
adjuvant to standard therapies. The activation of selective
forms of autophagy that degrade metabolically signiﬁcant
structures such as mitochondria, nuclei, and proteins may be
one feature of tumors that can be exploited to cripple tumor
survival.
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